This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
KRC-01 is an investigational product designed to improve the effectiveness of radiotherapy by increasing oxygen levels inside tumors, which may help radiation work better. KRC-01 contains hydrogen peroxide and sodium hyaluronate and is injected directly into the tumor before radiotherapy sessions.
Previous clinical experience in Japan, including studies in several types of cancer, suggested that this approach may improve tumor oxygenation and enhance the effect of radiotherapy.
The main objective of the K-BOOST study is to evaluate how many patients achieve a complete clinical response after treatment with chemoradiotherapy combined with intratumoral KRC-01 injections, potentially allowing some patients to avoid surgery. Surgery may still be recommended depending on the individual response to treatment.
Approximately 24 patients will participate in this multicenter French study. The experimental treatment period lasts approximately 26 weeks, and participants will be followed for up to 2 years.

开始日期2026-07-01

申办/合作机构

Gustave Roussy, Cancer Campus, Grand Paris

[+1]

CTIS2025-524378-40-00

/ Not yet recruiting临床2期IIT

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

开始日期2026-05-28

申办/合作机构

Institut Gustave Roussy EURL

NCT07534865

/ RecruitingN/AIIT

A Randomized, Parallel-Group, Controlled, Assessor-Blinded Clinical Trial of Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts

Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.
This study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.

开始日期2026-05-01

申办/合作机构

中国医科大学附属第一医院

100 项与过氧化氢相关的临床结果

登录后查看更多信息

100 项与过氧化氢相关的转化医学

登录后查看更多信息

100 项与过氧化氢相关的专利（医药）

登录后查看更多信息

185,344

项与过氧化氢相关的文献（医药）

2026-09-01·Infection Disease & Health

Comparative efficacy of preprocedural mouthwashes in reducing microbial aerosols during dental procedures: A network meta-analysis

Review

作者: Xiao, Yang ; Lin, Yuwei ; Li, Enhong ; Yu, Xuefen ; Hong, Feiruo ; Zhou, Qiuyu

BACKGROUND:

This study aimed to evaluate and rank the efficacy of common preprocedural mouthwashes in reducing microbial aerosols during dental procedures via network meta-analysis (NMA) and provide evidence-based guidance for clinical infection control.

METHODS:

We systematically searched eight electronic databases from inception to February 2025. Randomized controlled trials (RCTs) assessing mouthwashes for reducing microbial aerosols during dental procedures were included. A Bayesian NMA with a random-effects model was performed. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence was evaluated using the CINeMA framework. Surface under the cumulative ranking curve (SUCRA) and standardized mean difference (SMD) with 95% confidence interval (CI) were calculated to quantify intervention effects.

RESULTS:

Twenty-five RCTs involving 1111 participants and eight interventions were included. Compared with the control group, chlorhexidine (CHX) showed the largest effect (SMD = -7.10, 95% CI [-9.44, -4.73]), followed by herbal mouthwash (SMD = -5.16, 95% CI [-8.04, -2.17]) and povidone-iodine (PVP-I) (SMD = -4.57, 95% CI [-8.79, -0.21]). Efficacy ranking based on SUCRA values was as follows: CHX (0.90), cetylpyridinium chloride (CPC) (0.68), herbal mouthwash (0.61), PVP-I (0.53), essential oil mouthwash (0.44), normal saline (0.42), hydrogen peroxide (0.39), and control (0.03).

CONCLUSIONS:

CHX appears to be the most effective mouthwash for reducing microbial aerosols, with CPC and herbal mouthwashes as viable alternatives, particularly for patients with CHX intolerance or mucosal sensitivity. However, evidence for CPC is limited, and the overall certainty is low. Further well-designed RCTs are needed, especially to evaluate efficacy against viral aerosols.

2026-07-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Influence of Er:YAG laser activation and hydrogen peroxide concentration on esthetic efficacy, peroxide kinetics, diffusion, and thermal response during dental bleaching

Article

作者: Aidar, Karen Milaré Seicento ; Briso, André Luiz Fraga ; Junior, Fernando Costa ; Esteves, Lara Maria Bueno ; Silva, Marissa Geretti Timpurim ; Strazzi-Sahyon, Henrico Badaoui ; Correa, Jully Anna Cardoso ; Neto, Fernando Costa

BACKGROUND:

Laser-assisted in-office bleaching has been proposed to enhance whitening efficacy by accelerating hydrogen peroxide (H₂O₂) degradation and optimizing oxidative reactions. Nevertheless, Er:YAG laser influence on thermal behavior, peroxide kinetics, optical performance, and trans-amelodentinal diffusion remains insufficiently elucidated. Thus, this in-vitro study evaluated the combined effects of Er:YAG laser activation and different H₂O₂ gel concentrations on thermal, chemical, and optical responses during enamel bleaching.

METHODS:

186 bovine incisors were allocated into six groups according to H₂O₂ concentration (9%, 17.5%, and 35%) and Er:YAG irradiation (with or without activation). Phase I assessed temperature at the enamel surface and pulp chamber, and H₂O₂ degradation at distinct evaluation periods. Phase II evaluated chromatic alteration (ΔE₀₀), whitening index (WI_D) in relation to established perceptibility and acceptability thresholds, and trans-amelodentinal diffusion of H₂O₂. Statistical analyses were performed using ANOVA followed by Tukey post hoc tests (α = 0.05).

RESULTS:

Higher H₂O₂ concentrations resulted in significantly greater ΔE₀₀ and WI_D values; however, these effects were accompanied by increased temperature and peroxide diffusion. Notably, comparisons between the highest and lowest H₂O₂ gel concentrations, irrespective of laser irradiation, exceeded the established whitening perceptibility threshold. Er:YAG irradiation significantly accelerated H₂O₂ degradation and enhanced whitening outcomes compared with non-irradiated groups. Notably, laser activation reduced trans-amelodentinal peroxide diffusion across all evaluated H₂O₂ gel concentrations. Overall, reductions in temperature and H₂O₂ gel concentration were observed over time.

CONCLUSIONS:

Er:YAG-assisted bleaching modulates peroxide degradation kinetics, enhances whitening efficacy, and influences thermal and trans-amelodentinal peroxide diffusion.

2026-07-01·JOURNAL OF EQUINE VETERINARY SCIENCE

Molecular typing, biofilm characteristics and biofilm-targeted inhibition strategies of Streptococcus equi subsp. zooepidemicus isolated from donkey endometritis

Article

作者: Wang, Z ; Wang, Y ; Bai, X ; Luo, T ; Zhu, Y ; Liu, B ; Wang, T ; Zheng, Y ; Wu, C ; Ma, S ; Li, J ; Qu, H ; Yu, J

BACKGROUND:

Endometritis is a major cause of infertility in intensively farmed donkeys. Streptococcus equi subsp. zooepidemicus (SEZ) is a predominant pathogen that readily forms biofilms in equine endometritis, conferring resistance to conventional treatments.

AIMS/OBJECTIVES:

This study aimed to characterize the biofilm dynamics of SEZ isolates obtained from donkeys and to evaluate potential anti-biofilm strategies with different drug combinations.

METHODS:

Uterine lavage samples were collected from 30 Dezhou Black donkeys with clinical endometritis. Bacterial cultures were performed on blood agar and MacConkey agar. SEZ isolates were identified by 16S rDNA PCR sequencing. Antimicrobial sensitivity test of SEZ isolates was performed with broth microdilution methods. Multilocus sequence typing (MLST) was used for strain characterization, and in vitro biofilm dynamics were assessed using crystal violet assays. Six agents-Tris-EDTA, hydrogen peroxide, DMSO, penicillin potassium, ceftiofur, and ciprofloxacin-were tested individually or in combination for their inhibitory effects on SEZ biofilms.

RESULTS:

Thirteen SEZ isolates were obtained from a total of 31 bacterial isolates (41.9%), representing four novel MLST types: STnovel, ST554, ST555 and ST556. Rapid formation of biofilm was observed at 12-24 h. Strain-dependent inhibitory patterns were observed in SEZ biofilms. Hydrogen peroxide showed the strongest inhibitory effect on STnovel biofilms (73.73 ± 1.48%), while ceftiofur-Tris-EDTA, ciprofloxacin-DMSO and penicillin-DMSO combinations exhibited the highest inhibition against ST554 (66.52 ± 3.66%), ST555 (82.60 ± 2.97%) and ST556 (83.35 ± 1.19%) biofilms.

CONCLUSION:

Strain-dependent inhibitory patterns were observed in SEZ biofilms. Antibiotic-non-antibiotic combinations showed promising effects in vitro, highlighting new therapeutic avenues for controlling SEZ biofilm-associated infections in donkeys.

140

项与过氧化氢相关的新闻（医药）

2026-05-22

·GlobeNewswire-Health Care

Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology

Recent Ebola and Hantavirus Outbreaks Underscore Increasing Institutional Demand for Advanced Disinfection Solutions Across Hospitals, Hotels, Cruise Ships, Transportation Hubs, and Public FacilitiesFREDERICK, Md., May 22, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today highlighted the growing importance of advanced environmental disinfection solutions as global health officials raise alarms over the rapidly escalating Ebola outbreak in Central Africa. The World Health Organization (“WHO”) has stated they are “deeply concerned about the scale and speed of the epidemic” as the outbreak continues to expand across multiple regions. The outbreak, now classified as a Public Health Emergency of International Concern, reportedly involves more than 500 suspected cases and over 130 fatalities centered in the Democratic Republic of the Congo (“DRC”) and Uganda. WHO officials have also warned that the outbreak is expected to continue for months, raising concerns that strained healthcare systems, population displacement, and limited containment infrastructure could accelerate transmission risk. The outbreak involves the rare Bundibugyo strain of Ebola, a highly dangerous virus for which there is currently no broadly available approved vaccine, increasing urgency surrounding containment efforts and infection control preparedness. “As health authorities warn about the speed, scale, and expected duration of this Ebola outbreak, organizations around the world are being reminded that infectious disease preparedness is no longer optional,” said Dr. Halden Shane, CEO at TOMI Environmental Solutions. “Institutions are increasingly recognizing the need for scalable, rapid-response decontamination systems capable of addressing evolving biological threats.” TOMI has previously successfully helped contain an Ebola outbreak in West Africa. In collaboration with the WHO and supported by a USAID 'Fighting Ebola: A Grand Challenge for Development' grant, TOMI deployed SteraMist to help contain the spread of the virus. Teams utilized the system to secure high-risk "red zones" and safeguard healthcare personnel during the critical donning and doffing of protective gear. This application successfully prevented cross-contamination in the field, establishing SteraMist as a trusted partner in global health security. TOMI continues to support customers across healthcare, life sciences, hospitality, transportation, government, defense, and commercial sectors with technologies designed to help organizations rapidly respond to infectious disease threats and environmental contamination risks. For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the emergency sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Zach NevasIMS Investor Relationstomi@imsinvestorrelations.com

疫苗

2026-05-19

·GlobeNewswire-Health Care

TOMI™ Environmental Solutions Mobilizes SteraMist iHP Technology in Response to Emerging Global Pathogen Threats

Leveraging a Proven Legacy of Global Decontamination Leadership from the 2015 Ebola Response to Mitigate Emerging ThreatsFREDERICK, Md., May 19, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced the strategic mobilization of its SteraMist ionized Hydrogen Peroxide (iHP) technology in response to recent reported outbreaks of Ebola. Leveraging a proven history of rapid deployment during high-consequence biological events, TOMI is actively collaborating with Regional Emerging Special Pathogen Treatment Centers (RESPTCs) and specialized medical transportation groups to mitigate the risk of transmission. As health authorities monitor the escalation of this and other viral threats, the necessity for a validated, high-level disinfection protocol is paramount. TOMI’s expertise in managing viral hemorrhagic fevers is well-documented. During the 2015 Ebola outbreak, TOMI’s SteraMist iHP technology was instrumental in the decontamination of treatment units and transport vehicles, establishing the company as a trusted partner in global health security. Today, the company continues to support a nationwide network of RESPTCs, providing the essential infrastructure required to isolate and treat patients safely. “Our mission has always been to provide the ultimate device for infection control when the stakes are at their highest,” stated Dr. Halden Shane, CEO of TOMI Environmental Solutions. “By working alongside RESPTCs and specialized transport groups, we are ensuring that those on the front lines have access to the fastest and most effective decontamination technology available. Whether facing Ebola or other contagions, our SteraMist iHP decontamination technology is designed to neutralize the threat and restore safety to public and clinical spaces.” In addition to healthcare settings, TOMI is working closely with specialized transportation organizations that facilitate the movement of high-risk patients. SteraMist’s rapid turnaround time allows ambulances and aircraft to be decontaminated and returned to service in minutes, a vital factor during active outbreak responses where logistics and speed are essential to saving lives. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the emerging pathogen sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach Nevas IMS Investor Relations tomi@imsinvestorrelations.com

2026-05-14

·GlobeNewswire-Health Care

TOMI Environmental Solutions, Inc. Announces Second SteraMist Hybrid System Installation Contract with a World-Renowned East Coast Research University

FREDERICK, Md., May 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announce that we have been awarded the contract for a second installation of our SteraMist Hybrid System at a large historic prestigious research university on the East Coast. This new project will focus on the laboratory areas of the university, further enhancing their commitment to rigorous safety and sterilization protocols. Building on our successful prior collaboration with this university announced early January of this year, we will be working alongside familiar contractors to ensure a seamless integration of the SteraMist Hybrid System. We are excited to continue our partnership in delivering reliable decontamination solutions tailored to the university's highest specific needs. This installation represents yet another significant milestone in our integration pipeline, which has been a focal point of our communications. The successful deployment of the SteraMist Hybrid System in laboratory environments exemplifies our commitment to providing high-level, automated decontamination solutions that meet the stringent requirements of esteemed educational and research institutions. Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions, stated, “We are thrilled to partner with this university once again as we expand our presence in their lab areas. The SteraMist Hybrid System continues to demonstrate its reliability and effectiveness in high-stakes environments, and we look forward to further supporting their operational needs through this installation.” This project not only highlights TOMI's ongoing dedication to excellence in disinfection technologies but also reinforces our position as a trusted partner in the healthcare and research sectors. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the laboratory market. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach NevasIMS Investor Relations tomi@imsinvestorrelations.com

100 项与过氧化氢相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脂溢性角化病	美国	Aclaris Therapeutics, Inc.	2017-12-14
消毒剂	日本	Ebisu Yakuhin Kako KK	1986-03-01
伤口感染	中国	天津市东方广诚医药化工有限公司	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-17
跖疣	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-13
局部晚期直肠癌	临床2期	法国	KORTUC, Inc.	2026-07-01
复发性乳腺癌	临床2期	印度	KORTUC, Inc.	2020-06-16
复发性乳腺癌	临床2期	英国	KORTUC, Inc.	2020-06-16
局部晚期乳腺癌	临床2期	印度	KORTUC, Inc.	2020-06-16
局部晚期乳腺癌	临床2期	英国	KORTUC, Inc.	2020-06-16
黑色丘疹性皮病	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
可见病灶	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
局部晚期宫颈癌	临床1期	印度	KORTUC, Inc.	2026-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04659928 (CTgov)	临床4期	新型冠状病毒感染	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	鹽鏇蓋齋廠膚遞蓋廠夢(範醖鏇遞繭餘餘艱窪窪) = 膚齋製窪鑰選築鬱選壓鑰積鬱膚願蓋艱繭顧壓 (餘醖顧簾糧壓鏇獵積憲, 16.38) 更多	-	2025-07-08
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	鹽鏇蓋齋廠膚遞蓋廠夢(範醖鏇遞繭餘餘艱窪窪) = 選鹽膚鬱醖鏇選襯鏇顧鑰積鬱膚願蓋艱繭顧壓 (餘醖顧簾糧壓鏇獵積憲, 155.43) 更多
ASTRO2024	N/A	直肠癌	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	淵繭餘願鹹積顧艱鹽範(繭願夢願齋憲壓蓋淵繭) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC 襯鬱繭壓餘鑰壓夢觸簾 (築鬱廠願襯廠積範顧製 ) 更多	-	2024-10-01
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	临床4期	慢性牙周炎	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	繭顧齋製獵膚觸蓋餘簾(醖簾憲廠鑰淵醖壓鏇蓋) = 膚顧廠蓋鏇蓋鹹窪獵廠鑰餘衊鑰願鏇夢夢鹽淵 (鹹夢顧遞選選醖齋繭齋, 0.16) 更多	-	2022-12-21
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	繭顧齋製獵膚觸蓋餘簾(醖簾憲廠鑰淵醖壓鏇蓋) = 淵構築窪繭廠鹹憲鬱鬱鑰餘衊鑰願鏇夢夢鹽淵 (鹹夢顧遞選選醖齋繭齋, 0.05) 更多
NCT03812510 (CTgov)	临床3期	疣	426	hydrogen peroxide (A-101 45% (Active))	糧餘簾構遞築廠襯艱網 = 製夢遞窪簾簾鬱糧艱鑰鬱壓遞構淵憲繭窪繭築 (網衊糧襯顧願艱窪鑰糧, 廠鏇蓋艱膚餘顧夢構夢 ~ 簾醖廠製鹹鹽顧選醖齋) 更多	-	2020-11-23
				isopropyl alcohol (Isopropyl Alcohol and Water (Vehicle))	糧餘簾構遞築廠襯艱網 = 鹽襯繭夢簾窪繭願艱鹹鬱壓遞構淵憲繭窪繭築 (網衊糧襯顧願艱窪鑰糧, 鹽蓋願蓋鏇壓餘願鹹窪 ~ 觸醖鹽選獵範餘衊襯壓) 更多
NCT03691831 (CTgov)	临床3期	跖疣 \| 疣	502	Active (Active)	淵襯艱鏇範鏇製艱膚繭 = 構膚廠鏇範憲願鹽簾齋構鑰鑰醖積夢鏇夢襯鹽 (糧壓觸餘鑰餘鹽築鹹獵, 齋鏇範網醖繭鬱齋蓋膚 ~ 窪鑰繭網築窪積鹽築衊) 更多	-	2020-10-05
				Vehicle (Vehicle)	淵襯艱鏇範鏇製艱膚繭 = 膚壓鏇艱鹽蓋鬱築衊顧構鑰鑰醖積夢鏇夢襯鹽 (糧壓觸餘鑰餘鹽築鹹獵, 膚鑰蓋餘廠選淵鹹襯糧 ~ 蓋壓膚鏇顧鑰憲艱壓齋) 更多
NCT03687372 (CTgov)	临床3期	跖疣 \| 疣	503	vehicle	膚廠製願鬱齋淵鏇壓遞(鏇築繭廠餘獵蓋構糧範) = 鹹積夢製鹹範範窪範願製醖壓網壓鹽願廠餘齋 (襯顧選夢鏇鏇範選鏇網, 夢選襯襯範積糧觸範膚 ~ 願鬱鹹鏇醖網繭齋衊衊) 更多	-	2020-10-05
NCT03224598 (CTgov)	临床2期	黑色丘疹性皮病	39	A-101 Topical Solution 40% (No Medical Abrading)	範簾壓鏇鬱艱蓋積鏇遞(糧鏇築鏇鹽餘簾築遞鹹) = 遞齋構襯遞範鑰襯壓廠齋淵鏇積餘網廠齋淵鹹 (積製簾願顧鏇齋憲範艱, 0.52) 更多	-	2020-03-17
				A-101 Topical Solution 40% (Medically Abrading)	範簾壓鏇鬱艱蓋積鏇遞(糧鏇築鏇鹽餘簾築遞鹹) = 選鏇構鑰鏇衊鑰壓繭餘齋淵鏇積餘網廠齋淵鹹 (積製簾願顧鏇齋憲範艱, 0.90) 更多
NCT03487588 (SK-FAN, CTgov)	临床4期	脂溢性角化病	41	A-101 Topical Solution	構衊網鏇願蓋膚壓築構(壓鹽築餘憲願齋膚獵鬱) = 網憲齋壓壓選膚膚選製獵齋鏇網壓選鑰廠製範 (膚膚淵築衊遞衊夢餘鏇, 0.62) 更多	-	2019-10-02
NCT03148691 (CTgov)	临床2期	脂溢性角化病	253	A-101 (Vehicle)	顧獵壓艱衊網獵壓鹹壓(鬱鹽繭糧鏇醖糧鬱壓觸) = 願鬱齋艱鑰醖齋構糧顧鹹積構糧獵構蓋鬱遞鬱 (糧糧遞繭遞鹹鹽齋鑰範, 10.4) 更多	-	2019-05-06
				A-101 (A-101 Low Dose)	顧獵壓艱衊網獵壓鹹壓(鬱鹽繭糧鏇醖糧鬱壓觸) = 觸繭願構網糧壓築網艱鹹積構糧獵構蓋鬱遞鬱 (糧糧遞繭遞鹹鹽齋鑰範, 36.74) 更多
NCT03210337 (CTgov)	临床2期	疣	157	A-101 Topical Solution (Active)	餘淵獵積齋鹹淵築蓋觸(鑰蓋廠餘壓鹽築顧艱鹽) = 窪製獵構廠鏇齋鑰淵遞醖糧蓋觸醖鑰憲壓憲襯 (夢淵製廠淵糧淵構鏇願, 0.85) 更多	-	2019-05-01
				A-101 Vehicle Solution (Vehicle)	餘淵獵積齋鹹淵築蓋觸(鑰蓋廠餘壓鹽築顧艱鹽) = 鬱遞鬱齋壓淵壓築廠網醖糧蓋觸醖鑰憲壓憲襯 (夢淵製廠淵糧淵構鏇願, 0.49) 更多